Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany
Open Access
- 1 October 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (5), 2318-2330
- https://doi.org/10.1002/ehf2.12768
Abstract
Aims The aim of this paper was to analyse heart failure (HF) signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan (sac/val) in primary care and cardiology settings in Germany. Methods and results A retrospective cohort study of electronic medical records identified 1263 adults (aged >= 18 years) in the German IMS (R) Disease Analyzer database who were prescribed sac/val during 2016 and had at least 6 months of data following sac/val initiation. Clinical characteristics were collected during the 12 months before the first recorded sac/val prescription (index date) and 6 months post-index. Details of sac/val dose and prescription patterns were also recorded in the 6 months post-index. HF signs, symptoms, and all-cause hospital referrals were evaluated for 90 days pre-index and 30-120 days post-index. Most patients (62%) were prescribed the lowest sac/val dose of 24/26 mg twice daily (b.i.d.) at index; only 14% of patients initiated on 24/26 mg or 49/51 mg b.i.d. were up-titrated to the 97/103 mg b.i.d. target dose during the 6 months post-index, while 6% of patients initiated on either 49/51 mg or 97/103 mg b.i.d. were stably down-titrated. Evaluation of prescription patterns in relation to clinical characteristics did not clearly explain the reluctance to up-titrate in the majority of patients. More patients experienced HF signs or symptoms or all-cause referrals to hospital during the 90 days pre-index than during the 30-120 days post-index. Conclusions The majority of patients receiving sac/val are not up-titrated, contrary to recommendations of the EU summary of product characteristics; this is not fully explained by patients' clinical characteristics. Further research is required to understand the reasons for clinician inertia.Keywords
Funding Information
- Novartis Pharma (NA)
This publication has 26 references indexed in Scilit:
- Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trialEuropean Journal of Heart Failure, 2016
- Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVECirculation, 2016
- Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring SystemEuropean Journal of Heart Failure, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimensEuropean Journal of Heart Failure, 2016
- Secondary analysis of existing data: opportunities and implementation2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- The Global Health and Economic Burden of Hospitalizations for Heart FailureJournal of the American College of Cardiology, 2014
- Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term RegistryEuropean Journal of Heart Failure, 2013
- Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult populationEuropean Heart Journal, 2002